Neena Bitritto-Garg is the founder, president and CEO of Ensho Therapeutics. The company was borne out of Bitritto-Garg’s desire to make a difference in healthcare’s most challenging diseases, with a goal to develop better therapeutic agents where there are severe limitations today.
Bitritto-Garg has driven Ensho’s success to date. She founded the company by acquiring clinical-stage inflammatory bowel disease (IBD) assets from EA Pharma, a division of Eisai. Bitritto-Garg recruited to Ensho a seasoned executive team that includes a multicultural mix of talented individuals, 50% of whom are women. She has helped guide the research and development teams to enable Ensho to strategically plan its Phase II development program in patients with IBD that it intends to initiate in 2026.
Prior to founding Ensho, Bitritto-Garg spent nearly a decade as an equity research analyst covering the biotechnology sector, including the neuroscience and immunology spaces. She led biotech and biopharma equity research strategy at multiple global banks, including at Citigroup, where she was the head of U.S. biotechnology equity research. She values this experience for providing a broad understanding of the biotech industry and building strong relationships in both the financial community and industry generally.
Bitritto-Garg is a graduate of the Roy and Diana Vagelos Program in Life Sciences and Management at the University of Pennsylvania and holds dual degrees in biochemistry (Bachelor of Arts) from the College of Arts and Sciences and economics (Bachelor of Science) with a concentration in finance from Wharton.